VRDN Stock Overview
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.22 |
| 52 Week High | US$39.00 |
| 52 Week Low | US$10.93 |
| Beta | 0.93 |
| 1 Month Change | 36.67% |
| 3 Month Change | -9.89% |
| 1 Year Change | -37.38% |
| 3 Year Change | 2.93% |
| 5 Year Change | -63.79% |
| Change since IPO | -90.51% |
Recent News & Updates
Recent updates
Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt
Sep 12
Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?
May 15Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Apr 18Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?
Jan 08Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market
Sep 09Viridian Therapeutics board compensation committee approves inducement grants
Sep 02An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued
Aug 22Viridian Therapeutics Q2 2022 Earnings Preview
Aug 12Viridian Therapeutics gets a new COO
Jun 23Viridian Therapeutics (VRDN) Investor Presentation - Slideshow
Jun 08Viridian Therapeutics reports Q1 results
May 06Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry Opportunity
Dec 08Shareholder Returns
| VRDN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | 2.9% | 1.1% |
| 1Y | -37.4% | -7.7% | 11.9% |
Return vs Industry: VRDN underperformed the US Biotechs industry which returned -7.9% over the past year.
Return vs Market: VRDN underperformed the US Market which returned 11% over the past year.
Price Volatility
| VRDN volatility | |
|---|---|
| VRDN Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VRDN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VRDN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 86 | Steve Mahoney | https://www.viridiantherapeutics.com |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease.
Viridian Therapeutics, Inc. Fundamentals Summary
| VRDN fundamental statistics | |
|---|---|
| Market Cap | US$880.29m |
| Earnings (TTM) | -US$216.66m |
| Revenue (TTM) | US$347.00k |
2,610x
P/S Ratio-4.2x
P/E RatioIs VRDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRDN income statement (TTM) | |
|---|---|
| Revenue | US$347.00k |
| Cost of Revenue | US$160.53m |
| Gross Profit | -US$160.18m |
| Other Expenses | US$56.48m |
| Earnings | -US$216.66m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.12 |
| Gross Margin | -46,160.81% |
| Net Profit Margin | -62,437.75% |
| Debt/Equity Ratio | 7.1% |
How did VRDN perform over the long term?
See historical performance and comparison